Early Tumor Shrinkage Points to Good Erbitux Outcomes

Patients with advanced colorectal cancer whose tumors have gotten smaller six weeks after starting treatment with Erbitux had a much longer time before their cancer got worse and almost twice the overall survival as patients whose tumors didn’t shrink. Patients in the BOND study had already gotten worse on standard chemotherapy and were receiving either Erbitux®…  Read More

Primary Colorectal Tumors Can Be Safely Left in Place

When cancer has spread beyond the colon or rectum, the primary colorectal tumor can safely be left in place with only rare complications. Surgeons at Memorial Sloan Kettering Cancer Center in New York followed 233 patients who began chemotherapy without surgery to remove their primary colon or rectal tumor. Almost 90 percent never had a problem…  Read More

Almost There: Colon Cancer Clinical Trial Needs Six More Patients

NSABP C-10 needs only six more patients to complete enrollment and prepare to answer the question: Is it safe and effective to leave a primary tumor without symptoms in the colon or rectum and proceed directly to chemotherapy in patients with colon cancer that has spread to distant organs where it cannot be surgically removed, The trial…  Read More

Intense Combination Chemotherapy Enables Surgery for Initially Unresectable Colorectal Mets

Treated with a combination of three chemotherapy drugs, 1 in 5 patients whose colorectal cancer had spread too far for surgery were able to have operations to remove metastatic tumors.  After five years, a third of them were alive with no sign of cancer. Doctors in Italy treated 200 stage IV patients with a combination of…  Read More

NCCN Updates Guidelines to Include KRAS Testing

The National Comprehensive Cancer Network (NCCN) has updated their Clinical Practice Guidelines in Oncology for Colon Cancer to include testing tumors from patients with metastatic colon cancer for the KRAS gene.  The Guidelines also now say that cetuximab (Erbitux®) and panitumumab (Vectibix™) should only be given to patients whose tumors have normal (wild-type) KRAS.

Continuing Avastin Beyond Initial Cancer Progression Improves Survival Time

Continuing Avastin® (bevacizumab) beyond the time when advanced colorectal cancer gets worse helps patients, according to new study reports.  Patients who continued to receive Avastin with a new chemotherapy regimen after their cancer first progressed lived almost 12 months longer than patients who got more chemo but stopped Avastin.  Both groups did better than those who…  Read More